SCHEMBL1940436

SCHEMBL1940436

Cc1ccc(F)cc1NC(=O)Nc1cccc(C(=O)c2cn(C)c3ncnc(N)c23)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 8/20 0.60
ERBB4 Q15303 8/20 0.60
ERBB2 P04626 7/20 0.60
ERBB3 P21860 7/20 0.60
TEK Q02763 7/20 0.60
PDGFRB P09619 1/20 0.55
KDR P35968 3/20 0.55
NTRK1 P04629 5/20 0.52
NTRK2 Q16620 3/20 0.52
NTRK3 Q16288 1/20 0.52
KCNH2 Q12809 1/20 0.43
AURKA O14965 2/20 0.43
AURKB Q96GD4 2/20 0.43
IKBKE Q14164 1/20 0.43
MAPK1 P28482 2/20 0.43
MEN1 O00255 1/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43
KIT P10721 1/20 0.43
MET P08581 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1941623 0.90 EGFR (0.60) EGFRERBB4ERBB2ERBB3TEK
SCHEMBL1942915 0.90 PDGFRB (0.61) EGFRERBB4ERBB2ERBB3TEK
SCHEMBL1940894 0.89 PDGFRB (0.65) EGFRERBB4ERBB2ERBB3TEK
SCHEMBL1939949 0.89 PDGFRB (0.71) EGFRERBB4ERBB2ERBB3TEK
SCHEMBL1940609 0.88 EGFR (0.66) EGFRERBB4ERBB2ERBB3TEK
SCHEMBL1941089 0.88 PDGFRB (0.60) EGFRERBB4ERBB2ERBB3TEK
SCHEMBL1941192 0.87 EGFR (0.77) EGFRERBB4ERBB2ERBB3TEK
SCHEMBL1940925 0.86 EGFR (0.78) EGFRERBB4ERBB2ERBB3TEK
SCHEMBL1939937 0.86 EGFR (0.58) EGFRERBB4ERBB2ERBB3TEK
SCHEMBL1940205 0.86 TEK (0.62) EGFRERBB4ERBB2ERBB3TEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578751-B1 PYRROLOPYRIMIDINE DERIVATIVES PFIZER PROD INC (US) 2011-06-15 EP disclosed
US-7271262-B2 Pyrrolopyrimidine derivatives PFIZER INC (US) 2007-09-18 US disclosed
CN-1726218-A Pyrrolopyrimidine derivatives PFIZER PROD INC (US) 2006-01-25 CN disclosed
EP-1578751-A1 PYRROLOPYRIMIDINE DERIVATIVES Pfizer Products Inc. (US) 2005-09-28 EP disclosed
US-20050037999-A1 Pyrrolopyrimidine derivatives PFIZER INC 2005-02-17 US disclosed
WO-2004056830-A1 PYRROLOPYRIMIDINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050037999-A1 Pyrrolopyrimidine derivatives CCNA1, CCNT1, TP53 EGFR 2758/4885ERBB4 2759/4885ERBB2 2738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.